{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:29:48Z","timestamp":1788280188620,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Remnant cholesterol (RC) is the cholesterol content within triglyceride-rich lipoproteins. It promotes atherosclerotic cardiovascular disease beyond LDL cholesterol (LDL-C). The prognostic role of RC in patients with ST-segment elevation myocardial infarction (STEMI) is unknown. We aimed to estimate RC-related risk beyond LDL-C in patients with STEMI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A total of 6602 consecutive patients with STEMI treated with primary percutaneous coronary intervention (PCI) from 1999 to 2016 were included. Remnant cholesterol was calculated as total cholesterol minus LDL-C minus HDL cholesterol. Adjusted Cox models were used to estimate the association between continuous RC levels and all-cause mortality, cardiovascular death, ischaemic stroke, and recurrent myocardial infarction (MI) at long-term (median follow-up of 6.0 years). Besides, discordance analyses were applied to examine the risk of the discordantly high RC (RC percentile rank minus LDL-C percentile rank &amp;gt; 10 units) compared with the discordantly low RC (LDL-C percentile rank minus RC percentile rank &amp;gt; 10 units). The concordance was defined as the percentile rank difference between RC and LDL-C \u2264 10 units. The median age of patients was 63 years [interquartile range (IQR) 54\u201372] and 74.8% were men. There were 2441, 1651, and 2510 patients in the discordantly low RC group, concordant group, and discordantly high RC group, respectively. All outcomes in the discordantly high RC group were higher than the other groups, and the event rate of all-cause mortality in this group was 31.87%. In the unadjusted analysis, the discordantly high RC was associated with increased all-cause mortality [hazard ratio (HR) 1.82, 95% confidence interval (CI) 1.63\u20132.04] and increased cardiovascular death (HR 1.79, 95% CI 1.55\u20132.06) compared with the discordantly low RC. In an adjusted model, RC was associated with higher all-cause mortality (HR 1.14, 95% CI 1.07\u20131.22). The discordantly high RC was associated with increased all-cause mortality (adjusted HR 1.55, 95% CI 1.37\u20131.75) and increased cardiovascular death (adjusted HR 1.47, 95% CI 1.25\u20131.72) compared with the discordantly low RC. There were no associations between RC and ischaemic stroke or recurrent MI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients with STEMI treated with primary PCI, elevated RC levels beyond LDL-C and discordantly high RC were independently associated with increased all-cause mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae102","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T19:47:02Z","timestamp":1709754422000},"page":"1227-1237","source":"Crossref","is-referenced-by-count":20,"title":["The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5094-4809","authenticated-orcid":false,"given":"Yan","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"},{"name":"Graduate School of Health and Medical Sciences, University of Copenhagen , Blegdamsvej 3B, 2200, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine Melissa","family":"Madsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu Tas","family":"\u00d6zbek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Evi","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Thomsen","family":"L\u00f8nborg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-9194","authenticated-orcid":false,"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, 2100, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2024080903361539400_zwae102-B1","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2014.08.037","article-title":"Short- and long-term cause of death in patients treated with primary PCI for STEMI","volume":"64","author":"Pedersen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024080903361539400_zwae102-B2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jacc.2013.01.007","article-title":"Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry)","volume":"61","author":"Fokkema","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024080903361539400_zwae102-B3","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2024080903361539400_zwae102-B4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/STROKEAHA.113.004229","article-title":"Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients","volume":"45","author":"Sirimarco","year":"2014","journal-title":"Stroke"},{"key":"2024080903361539400_zwae102-B6","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B7","doi-asserted-by":"crossref","first-page":"e005549","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2024080903361539400_zwae102-B8","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B9","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1093\/eurheartj\/ehab432","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024080903361539400_zwae102-B11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"2024080903361539400_zwae102-B12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/2047487319887578","article-title":"Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease","volume":"27","author":"Elshazly","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2024080903361539400_zwae102-B13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ahj.2021.04.012","article-title":"Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction","volume":"238","author":"Madsen","year":"2021","journal-title":"Am Heart J"},{"key":"2024080903361539400_zwae102-B14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/CLEP.S99475","article-title":"The Danish Heart Registry","volume":"8","author":"\u00d6zcan","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2024080903361539400_zwae102-B15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2024080903361539400_zwae102-B16","first-page":"798","article-title":"Data resource profile: The Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2024080903361539400_zwae102-B17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.24326","article-title":"Plasma levels of apolipoprotein E and risk of dementia in the general population","volume":"77","author":"Rasmussen","year":"2015","journal-title":"Ann Neurol"},{"key":"2024080903361539400_zwae102-B18","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B19","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-020-01076-7","article-title":"The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes","volume":"19","author":"Cao","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2024080903361539400_zwae102-B21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"2024080903361539400_zwae102-B22","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(21)00272-5","article-title":"Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data","volume":"397","author":"Figtree","year":"2021","journal-title":"Lancet"},{"key":"2024080903361539400_zwae102-B25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12916-022-02418-w","article-title":"Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"key":"2024080903361539400_zwae102-B26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","article-title":"Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B27","first-page":"132","article-title":"Impact of peripheral vascular disease on short- and long-term outcomes in patients undergoing non-emergent percutaneous coronary intervention in the drug-eluting stent era","volume":"25","author":"Midwall","year":"2013","journal-title":"J Invasive Cardiol"},{"key":"2024080903361539400_zwae102-B28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/clc.23116","article-title":"Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: results from the EPICOR registry","volume":"42","author":"Rossello","year":"2019","journal-title":"Clin Cardiol"},{"key":"2024080903361539400_zwae102-B29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ccd.28096","article-title":"Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: analysis from the HORIZONS-AMI trial","volume":"94","author":"Huang","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2024080903361539400_zwae102-B30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.acvd.2019.06.012","article-title":"In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: results from the French registry on acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort","volume":"112","author":"Ederhy","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"2024080903361539400_zwae102-B31","doi-asserted-by":"crossref","first-page":"e002460","DOI":"10.1161\/CIRCHEARTFAILURE.115.002460","article-title":"Mortality associated with heart failure after myocardial infarction: a contemporary community perspective","volume":"9","author":"Gerber","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2024080903361539400_zwae102-B32","doi-asserted-by":"crossref","first-page":"e009535","DOI":"10.1136\/bmjopen-2015-009535","article-title":"Quantifying the risk of heart disease following acute ischaemic stroke: a meta-analysis of over 50,000 participants","volume":"6","author":"Gunnoo","year":"2016","journal-title":"BMJ Open"},{"key":"2024080903361539400_zwae102-B33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/01.CIR.0000028146.71416.2E","article-title":"Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy","volume":"106","author":"Ellis","year":"2002","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12933-019-0972-4","article-title":"Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study","volume":"18","author":"Bromage","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2024080903361539400_zwae102-B35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ehjcvp\/pvaa004","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction","volume":"7","author":"Trevisan","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024080903361539400_zwae102-B36","doi-asserted-by":"crossref","first-page":"e000852","DOI":"10.1136\/openhrt-2018-000852","article-title":"Culprit vessel: impact on short-term and long-term prognosis in patients with ST-elevation myocardial infarction","volume":"5","author":"Entezarjou","year":"2018","journal-title":"Open Heart"},{"key":"2024080903361539400_zwae102-B37","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B38","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2024080903361539400_zwae102-B40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cca.2016.08.012","article-title":"Remnant lipoprotein size distribution profiling via dynamic light scattering analysis","volume":"462","author":"Chandra","year":"2016","journal-title":"Clin Chim Acta"},{"key":"2024080903361539400_zwae102-B41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacc.2022.11.013","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk","volume":"81","author":"Duell","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024080903361539400_zwae102-B42","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024080903361539400_zwae102-B43","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B44","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","article-title":"Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study","volume":"41","author":"Kaltoft","year":"2020","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B45","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00f6m","year":"2022","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"key":"2024080903361539400_zwae102-B47","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/2047487319899622","article-title":"Beyond LDL-C levels, does remnant cholesterol estimation matter?","volume":"27","author":"Pirillo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2024080903361539400_zwae102-B48","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000146898.06923.80","article-title":"Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study","volume":"110","author":"M\u00e4rz","year":"2004","journal-title":"Circulation"},{"key":"2024080903361539400_zwae102-B49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"2024080903361539400_zwae102-B50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2016.08.005","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","volume":"253","author":"Ballantyne","year":"2016","journal-title":"Atherosclerosis"},{"key":"2024080903361539400_zwae102-B51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2024080903361539400_zwae102-B52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024080903361539400_zwae102-B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"2024080903361539400_zwae102-B54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024080903361539400_zwae102-B55","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijcard.2012.01.009","article-title":"The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention","volume":"167","author":"Oduncu","year":"2013","journal-title":"Int J Cardiol"},{"key":"2024080903361539400_zwae102-B56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00380-017-1111-3","article-title":"Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome","volume":"33","author":"Nakahashi","year":"2018","journal-title":"Heart Vessels"},{"key":"2024080903361539400_zwae102-B57","first-page":"227","article-title":"Low admission LDL-cholesterol is associated with increased 3-year all-cause mortality in patients with non ST segment elevation myocardial infarction","volume":"16","author":"Al-Mallah","year":"2009","journal-title":"Cardiol J"},{"key":"2024080903361539400_zwae102-B58","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/joim.13656","article-title":"Elevated low-density lipoprotein cholesterol: an inverse marker of morbidity and mortality in patients with myocardial infarction","volume":"294","author":"Schubert","year":"2023","journal-title":"J Intern Med"},{"key":"2024080903361539400_zwae102-B59","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2024080903361539400_zwae102-B60","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1177\/2047487320937489","article-title":"Not only the status of body weight and metabolic health matters for cardiovascular events, but also the temporal changes","volume":"28","author":"Christou","year":"2022","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae102\/57086756\/zwae102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/10\/1227\/58778472\/zwae102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/10\/1227\/58778472\/zwae102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T03:37:02Z","timestamp":1723174622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/10\/1227\/7623124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,3,6]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae102","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,6]]}}}